![]() |
上海源葉生物科技有限公司
主營產(chǎn)品: S30260異硫氰酸胍,30259鹽酸胍,嗜熱菌蛋白酶 |
![](/NewShowStand/style/15/Images/Green/中級會員.png)
15
聯(lián)系電話
15921386130
公司信息
- 聯(lián)系人:
- 何小姐
- 電話:
- 86-021-61559134
- 手機(jī):
- 15921386130
- 傳真:
- 86-021-55068248
- 地址:
- 上海市松江區(qū)長塔路465號6幢
- 郵編:
- 200433
- 網(wǎng)址:
- www.shyuanye.com
S80100
參考價 | 面議 |
具體成交價以合同協(xié)議為準(zhǔn)
- 型號
- 品牌
- 廠商性質(zhì) 生產(chǎn)商
- 所在地
更新時間:2024-07-03 21:27:37瀏覽次數(shù):148
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!
- 提示:詳情請下載說明書。
- 產(chǎn)品描述: Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research
- 靶點(diǎn): hPPARγ:0.93 μM (EC50);mouse PPARγ:0.99 μM (EC50);hPPARδ:43 μM (EC50);hPPARα:100 μM (EC50);mouse PPARα:100 μM (EC50)
- 體內(nèi)研究: Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle. Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia.
- 參考文獻(xiàn):
1. Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve 2. Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. 3. Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. 4. Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33.
- 溶解度: DMSO : 40 mg/mL (112.22 mM; ultrasonic and warming and heat to 60°C)
- 保存條件: 2-8℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 2.545 ml 12.726 ml 25.452 ml 5 mM 0.509 ml 2.545 ml 5.09 ml 10 mM 0.255 ml 1.273 ml 2.545 ml 50 mM 0.051 ml 0.255 ml 0.509 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的性,僅供客戶參考交流研究之用。